DHPC Evrysdi▼ (risdiplam) 0.75 mg/mL powder for oral solution (PfOS)
The DMRC has requested for Roche to put in place a Direct Healthcare Professional Communication (DHPC) letter to communicate finding Polytetrafluorethylene (PTFE-Teflon) particles in EVRYSDI powder for oral solution.
The scope of the DHPC should explain potential presence of particles in specific batches and the corrective and preventative actions to be taken